The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation Reduction Act designed to reduce health care costs. HHS said the selected drugs accounted for $50.5 billion in total Part D gross covered prescription drug costs, or about 20%, of total Part D gross covered prescription drug costs between June 1, 2022, and May 31, 2023.

Drugmakers will need to sign agreements to join negotiations by Oct. 1, with the Center for Medicare & Medicaid Services making initial price offers in February 2024. The drugmakers will then have a month to accept or make a counteroffer. The resulting agreed-upon negotiated prices for the 10 drugs will be published by CMS by Sept. 1, 2024, with the prices taking effect Jan. 1, 2026. Additional drugs could be added to the list in future years.

Drugmakers that decline to negotiate the prices of selected drugs with CMS will be required to either pay an excise tax of up to 95% of U.S. sales or pull all its products from the Medicare and Medicaid markets.

Related News Articles

Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
A JAMA study published Aug. 18 found that plan design changes by Medicare Part D insurers, particularly for Medicare Advantage plans, following passage of the…
Headline
The Centers for Medicare & Medicaid Services today announced a nationwide initiative aimed at reinforcing eligibility standards for Medicaid and the…
Headline
The Centers for Medicare & Medicaid Services has issued the 2025-2026 Medicaid Managed Care Rate Development Guide for states to use when setting managed…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…